Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease AssayBusiness Wire • 03/07/23
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical TrialsBusiness Wire • 02/03/23
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal CancerBusiness Wire • 11/30/22
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingBusiness Wire • 11/07/22
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics BusinessBusiness Wire • 10/31/22
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal CancerBusiness Wire • 10/04/22
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 08/30/22
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight DiagnosticsBusiness Wire • 08/17/22
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic CancersBusiness Wire • 08/15/22